(RTTNews) - Moderna, Inc (MRNA) shares suffered their steepest decline since August after leaked late-stage trial results for its personalized melanoma vaccine showed a smaller risk reduction than an earlier study.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.